Search Results
Your search for The ASCO Post matches 18362 pages
Showing 1 - 50Better Together: The Case for True Physician-AP Partnership in Oncology
At 8 am, the infusion chairs are already full. The oncologist is in a room seeing a new patient consult, the pharmacist is adjusting doses based on new lab values, and the advanced practitioner (AP) is sitting with a patient—reviewing symptoms, discussing how to manage treatment side effects, and ...
I Have Advanced-Stage Lung Cancer. I Refuse to Be a Victim of the Disease
I remember thinking on the day I turned 60, May 10, 2021, “This is going to be the best year of my life.” I couldn’t have been more wrong. Within weeks of feeling that swell of optimism about my future, I began experiencing a series of odd, and, seemingly unrelated symptoms leading to my eventual...
A Timely Compendium for the Era of Precision Oncology
The pace at which precision oncology has evolved over the past 2 decades, from the early promise of the Human Genome Project to the clinical reality of CAR T-cell therapy, antibody drug conjugates, and AI-assisted decision support, has made it increasingly difficult for even the most engaged...
Using Artificial Intelligence to Prescribe Cancer Drugs and Perform Other Tasks
In a recent article in The ASCO Post, we discussed increasing use of artificial intelligence (AI) in oncology and how physician-complementing AI can empower oncologists to be even better at what they do.1The reason AI is needed is that increasingly many variables need to be considered in cancer...
Facing a Year Ahead of Unprecedented Opportunities—and Challenges
This year has marked unprecedented progress against cancer—as well as challenges. According to findings in the American Cancer Society’s Cancer Statistics, 2026 report, the 5-year relative survival rate for all cancers combined has reached a milestone of 70% for individuals diagnosed between 2015...
ASCO Expands Landmark TAPUR™ Trial
ASCO has expanded its Targeted Agent and Profiling Utilization Registry (TAPUR™) Study with two new developments: The study added its first antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (T-DXd), to determine if a wider group of patients would benefit from this medicine. Separately, the...
Four Ways AI Is Transforming Patient Care—and What Lies Ahead
During her Presidential address at the 2025 ASCO Annual Meeting, Robin T. Zon, MD, FACP, FASCO, assessed how artificial intelligence (AI) is driving knowledge into action in the field of oncology, and acknowledged that “we are now at the crossroads of long-imagined possibilities and actionable...
Uniting Science, Practice, and Purpose for Better Cancer Care
Growing up as an American in Mexico City, I couldn’t have grasped how that upbringing would eventually shape my professional identity. While a career in oncology was far from my mind then, that cross-cultural foundation deeply influenced my approach to medicine and my leadership as ASCO’s 62nd...
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
On May 22, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), an antibody-drug conjugate targeting trophoblast cell surface antigen 2 (TROP2), for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for ...
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Although treatment advances have increased the 5-year relative survival rates across all age groups, including a 15% increase for adolescents and young adults ages 15 to 39 years,1 it varies widely for some cancers among AYAs who are diagnosed with cancer. For example, AYAs have substantially worse ...
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
In two complementary preclinical studies published in Blood, investigators reported that mezigdomide, a cereblon E3 ligase modulator, may help overcome T-cell dysfunction in multiple myeloma, thereby enhancing the activity of BCMA-directed CAR T-cell and bispecific T-cell engager therapies. These...
Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors
A 4-week structured yoga intervention improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase III randomized controlled trial that will be presented at the 2026 ASCO Annual Meeting (Abstract 12004). The analysis also suggested that...
AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans
A new study has shown that AI avatar–based digital patient engagement prior to in-person radiation treatment consultations may enable patients to feel more knowledgeable and less stressed than patients who did not engage with an AI avatar, according to findings presented during the Congress of the...
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
Researchers have developed a novel diagnostics tool to detect gene fusions in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with greater sensitivity than standard detection algorithms, according to findings from a study published in The Journal of Molecular Diagnostics. The researchers...
Study Shows Potential Missing Patient Information in SEER Database
A significant number of patients with cancer—particularly those with more advanced disease who are more likely to receive care at community hospitals, safety net hospitals, and rural medical centers—may have incomplete case information in the Surveillance, Epidemiology, and End Results (SEER)...
Patients With IBD May Be at Risk for VTE After Colorectal Cancer Surgery
Patients with inflammatory bowel disease (IBD) may be at a greater risk for postoperative venous thromboembolism (VTE) at least 30 days after surgery for colorectal cancer, according to the results of a large, retrospective study presented at the 2026 Digestive Disease Week Conference. “These...
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
A new meta-analysis published by Costa et al in JNCCN—Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief...
Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade
A new study shows that cases of stage IV breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published by Avila et al in JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly from 9.5...
How Conquering Cancer Is a Team Effort
After finishing her academic studies, Dr. Mittendorf enlisted in the U.S. Air Force—an experience that would propel her into the field of oncology. “My second day on active duty was September 11, 2001,” said Dr. Mittendorf. “I was an attending surgeon at Walter Reed Army Medical Center (now called...
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17-inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer—now sometimes described as androgen pathway modulation–resistant (APMR) (or modulation-sensitive ...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer
On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive early-stage breast cancer. The first indication is for the neoadjuvant treatment of adult...
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer
On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA...
Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study
Sigmoidoscopy screening led to reduced incidence of colorectal cancer, though more for men vs women, and a reduced rate of colorectal cancer–related mortality in men, according to findings from the randomized, controlled NORCCAP trial published in the Annals of Internal Medicine. Background and...
Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients
An international research team has shown that a specific subtype of diffuse large B-cell lymphoma (DLBCL) is associated with higher mortality risk in women than in men. The study was led by the laboratory of Ari Melnick, MD, Director of the Josep Carreras Leukaemia Research Institute and the Gebroe ...
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?
A systematic review and meta-analysis published in JAMA Network Open found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers. According to Inoue et al, this association appeared to be particularly pronounced in non–small cell lung...
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
On May 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor....
FDA Approves Combination Regimen for Newly Diagnosed AML
On May 13, the U.S. Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine tablets (Inqovi) plus venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older or who have comorbidities that preclude them from...
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
Hundreds of thousands of people diagnosed with cancer are still alive today, but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those diagnosed today to carry a germline...
Inherited Long Telomeres May Increase the Risk of Lymphoid Cancers
Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins have identified a genetic syndrome in which unusually long telomeres—the protective caps at the ends of chromosomes—allow immune cells to remain biologically “younger” for longer than normal, predisposing ...
Inflammatory Breast Cancer: Blood-Based Biomarkers Identified
Researchers have identified blood-based biomarkers in tumors, peripheral blood cells, and plasma that may help to differentiate between inflammatory breast cancer and non–inflammatory breast cancer, according to findings published in Science Advances. “These findings provide new insights into...
New Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma
A clinical whole-genome sequencing test for patients with multiple myeloma, JAYseq, has been launched at the Translational Genomics Research Institute (TGen). “The launch of JAYseq represents a meaningful step in oncology testing, one that allows physicians to make a more precise treatment...
Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer
A new urine test performed better than prostate specific antigen (PSA)-based testing and magnetic resonance imaging (MRI) for monitoring patients with low-risk prostate cancer on active surveillance. Use of the test to determine the need for repeat “monitoring” biopsies would have avoided up to 64% ...
First Virtual Cancer Clinic to Receive ASCO Certified Status
ASCO has certified its first virtual cancer clinic from Color, a company that owns and operates a nationwide, oncologist-led Virtual Cancer Clinic, serving employer, union, health plan, and public sector populations. The ASCO Certified status indicates that the virtual practice meets a high set of...
FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic NRG1-Mutated Cholangiocarcinoma
The U.S. Food and Drug Administration (FDA) approved the HER2- and HER3-directed bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. The...
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
National Academy of Medicine Recognizes 100 Newly Elected Members
Overview of Member Election Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current members through a process that acknowledges individuals who have made major...
ARS Honors Thomas Buchholz, MD, With 2026 Gold Medal Award
The American Radium Society (ARS) presented its 2026 Gold Medal Award to Scripps Cancer Center Medical Director Thomas Buchholz, MD, at its Annual Meeting in Newport Beach, California. The Gold Medal Award is the organization’s highest honor for a member who has made significant contributions to...
Could AI Be Licensed to Practice Oncology?
Is artificial intelligence (AI) poised to practice medicine? It may be already. Earlier this year, the state of Utah allowed Doctronic, a health technology company using AI to make clinical decisions autonomously, to renew prescriptions for patients who request the service. Although Utah’s pilot...
Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures
Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occurring in low- and middle-income countries.1 Delays in obtaining an accurate diagnosis,...
LLM Tool Significantly Reduces Participant Screening Burdens, Improves Enrollment for Phase III Trial in Polycythemia Vera
Synapsis AI, a medically trained, large language model (LLM)–based end-to-end system, reduced the time and effort needed to screen for eligible patients to participate in a randomized, interventional phase III clinical trial in patients with polycythemia vera (PV). Use of Synapsis AI also led to...
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing Cytoreductive Surgery
A retrospective study found that levels of commonly measured serum tumor markers—CEA, CA19-9, and CA125—can play a significant role in predicting outcomes in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy...
High YAP1 Expression Leads to Chemotherapy Resistance, Relapse in Treated SCLC
Expression of the YAP1 protein following treatment with chemotherapy is associated with the development of treatment resistance and cancer relapse in patients with small cell lung cancer (SCLC), according to findings from an analysis published in Journal of Thoracic Oncology. The researchers...
AI Pathology Framework for Biological Understanding of Tumors
An agentic artificial intelligence (AI) framework may help researchers gain a better understanding of hidden biological information of tumors, according to a study published in Nature Medicine. “SPARK helps to refine diagnoses, stratify patients more reliably, and make more precise treatment...
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alone. Interim results from the CLIMATE study found post-orchiectomy plasma miR-371a-3p (miR-371), a...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
Breast Density Reduction: Endoxifen vs Tamoxifen
Low doses of the investigational agent endoxifen reduced breast density to the same extent as the standard treatment tamoxifen, with fewer adverse events, according to results from the KARISMA study, a proof-of-principle, dose-determining, double-blinded, randomized, placebo-controlled trial. These ...
Advanced CKM Syndrome Associated With Greater Cancer Risk
Advanced cardiovascular-kidney-metabolic (CKM) syndrome may be associated with an increased risk of developing cancer, according to findings from a Japanese study published in Circulation: Population Health and Outcomes. “The study findings suggest that it is important to consider not only...
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
Investigators used data from the Surveillance, Epidemiology, and End Results (SEER) database to analyze trends in multiple myeloma mortality in the United States from 1975 to 2023. Their findings were published in Oncotarget. The study was led by first and corresponding author Navkirat Kahlon, MD,...
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by...
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
On May 1, the U.S. Food and Drug Administration announced that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib. In mid-April, Revolution Medicines...
